"SURVIVAL in adults with SR-aGVHD who have failed at least one additional agent, such as ruxolitinib,
remains as low as 20-30% by 100 days.1,2 In contrast, 100-day SURVIVAL was 73% after Ryoncil®"
So, survival vs survival. A direct comparison of rux vs rem-l efficacy would require an RCT that has never been done. I don’t believe the company is trying to make such a comparison. Rather, they've ceded the secondary therapy slot to ruxilitinib, at least for the time being.
MSB Price at posting:
$3.17 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)